Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity

Clinics

Volumn 67, Issue 9, 2012, Pages 1117-1121

  Pesaro, Antonio Eduardo P ^a,b   Serrano, Carlos V ^b   Katz, Marcelo ^a,b   Campos, Alexandre H ^a,b   Lopes, Renato D ^b,c,d   Marti, Luciana C ^a,b   Martins, Herlon S ^b,d   Sunahara, Rodrigo S ^b,c   Maranhao, Raul C ^b   Nicolau, José C ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867159166     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(09)21     Document Type: Article

References (33)

1. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213-20, http:// dx.doi.org/10.1253/circj.CJ-09-0706.
2. Daub K, Seizer P, Stellos K, Krämer BF, Bigalke B, Schaller M, et al. Oxidized LDL-activated platelets induce vascular inflammation. Semin Thromb Hemost. 2010;36(2):146-56, http://dx.doi.org/10.1055/s-0030-1251498.
3. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost. 2007;97(5):704-13.
4. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600, http:// dx.doi.org/10.1056/NEJMoa022287.
5. Abou-Saleh H, Yacoub D, Théorêt JF, Gillis MA, Neagoe PE, Labarthe B, et al. Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation. 2009;120(22):2230-9, http:// dx.doi.org/10.1161/CIRCULATIONAHA.109.894642.
6. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195-8.
7. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142(5):370-80.
8. Cavalcanti AB, Campos AH, Martins HS, Maranhão RC, et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2011. [Epub ahead of print]
9. Böck M, De Haan J, Beck KH, Hertfelder HJ, Karger R, Heim MU, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol. 1999;106(4):898-904, http://dx.doi.org/10.1046/j.1365-2141.1999.01660.x.
10. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-9, http://dx.doi.org/10.1182/blood-2006-08-043471.
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-65, http:// dx.doi.org/10.1056/NEJMoa021993.
12. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348(12):1104-11, http://dx.doi.org/ 10.1056/NEJMoa022600.
13. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353(1):46-57, http://dx.doi.org/10.1056/ NEJMoa043175.
14. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702-8, http:// dx.doi.org/10.1093/eurheartj/ehm226.
15. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost. 2008;99(1):14-26.
16. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24(2):195-202, http:// dx.doi.org/10.1055/s-2007-995840.
17. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6(3):444-50, http://dx.doi.org/10.1111/j.1538-7836.2008.02897.x.
18. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost. 2008;99(3):480-6.
19. Relou IA, Hackeng CM, Akkerman JW, Malle E. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci. 2003;60(5):961-971.
20. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA. 2003;100(21):12367-71, http://dx.doi.org/10.1073/pnas.2032886100.
21. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002;106(4):399-402, http://dx.doi.org/10.1161/01.CIR.0000025419.95769.F0.
22. Scheuerer B, Ernst M, Dü rrbaum-Landmann I, Fleischer J, Grage-Griebenow E, Brandt E, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood. 2000;95(4):1158-66.
23. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD-40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17(4):118-23, http://dx.doi.org/10.1016/j.tcm.2007.02.004.
24. Dotsenko O, Chaturvedi N, Thom SA, Wright AR, Mayet J, Shore A, et al. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J Thromb Haemost. 2007;5(10):2036-42, http://dx.doi.org/10.1111/j.1538-7836.2007.02711.x.
25. Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, et al. The balance between pro-and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis. 2009;202(1):255-62, http://dx.doi.org/10.1016/ j.atherosclerosis.2008.04.001.
26. Obradovic SD, Antovic JP, Antonijevic NM, Ratkovic NG, Vojvodic DV, Subota VS, et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2009;20(4):283-9, http://dx.doi.org/10.1097/ MBC.0b013e328329f28c.
27. Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US. The link between heightened thrombogenicity and inflammation: preprocedure characterization of the patient at high risk for recurrent events after stenting. Platelets. 2009;(2):97-104, http://dx.doi.org/10.1080/ 09537100802687666.
28. Pamukcu B, Oflaz H, Onur I, Midilli K, Yilmaz G, Yilmaz E, et al. Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease. Circ J. 2008;72(1):61-6, http://dx.doi.org/10.1253/circj.72.61.
29. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981-7, http:// dx.doi.org/10.1161/CIRCULATIONAHA.104.504340.
30. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arteriosclerosis, thrombosis, and vascular biology. 2003;23(7):1185-9, http://dx.doi.org/10.1161/01.ATV.0000073832. 49290.B5.
31. Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clinical and experimental pharmacology & physiology. 2004;31(7):407-13, http://dx.doi.org/10.1111/j.1440-1681.2004.04022.x.
32. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. The New England journal of medicine. 2005;353(10):999-1007, http:// dx.doi.org/10.1056/NEJMoa043814.
33. Stellos K, Seizer P, Bigalke B, Daub K, Geisler T, Gawaz M. Platelet aggregates-induced human CD34+ progenitor cell proliferation and differentiation to macrophages and foam cells is mediated by stromal cell derived factor 1 in vitro. Semin Thromb Hemost. 2010;36(2):139-45, http://dx.doi.org/10.1055/s-0030-1251497.